The aim of this prospective observational study is to determine the different outcomes of IVF/ICSI treatments after using antagonists or agonists of gonadotrophin-releasing hormone (GnRH) for controlled ovarian hyperstimulation (COH) in normal responder patients. Two hundred forty-seven patients undergoing IVF treatment at the Centre of Reproductive Medicine, Rome (CERMER), from January 2005 to December 2008, were included in the study. Patients were stimulated either with a standard long protocol with GnRH agonists (n=156) or with GnRH antagonists (n=91). The use of GnRH antagonists resulted in a significant reduction in the duration of the stimulation (Agonist Group 14.10±2.25 vs. Antagonist Group 11.34±2.11; P<0.001) and in the amount of gonadotrophin (IU of r-FSH) needed (Agonist Group 1878±1109 vs. Antagonist Group 1331±1049; P=0.0014). Moreover a lower number of cycles were cancelled with the antagonist protocol (4.39% vs 6.41%). The GnRH antagonist protocol, when compared to the GnRH agonist one, is associated with a similar clinical pregnancy rate, similar implantation rate, significantly lower gonadotrophin requirement and shorter duration of stimulation. For this reason, GnRH antagonists might be a good treatment even for normal responder patients undergoing IVF.
In Vitro Fertilization stimulation protocol for normal responder patients
MARCI, Roberto;SOAVE, Ilaria;
2013
Abstract
The aim of this prospective observational study is to determine the different outcomes of IVF/ICSI treatments after using antagonists or agonists of gonadotrophin-releasing hormone (GnRH) for controlled ovarian hyperstimulation (COH) in normal responder patients. Two hundred forty-seven patients undergoing IVF treatment at the Centre of Reproductive Medicine, Rome (CERMER), from January 2005 to December 2008, were included in the study. Patients were stimulated either with a standard long protocol with GnRH agonists (n=156) or with GnRH antagonists (n=91). The use of GnRH antagonists resulted in a significant reduction in the duration of the stimulation (Agonist Group 14.10±2.25 vs. Antagonist Group 11.34±2.11; P<0.001) and in the amount of gonadotrophin (IU of r-FSH) needed (Agonist Group 1878±1109 vs. Antagonist Group 1331±1049; P=0.0014). Moreover a lower number of cycles were cancelled with the antagonist protocol (4.39% vs 6.41%). The GnRH antagonist protocol, when compared to the GnRH agonist one, is associated with a similar clinical pregnancy rate, similar implantation rate, significantly lower gonadotrophin requirement and shorter duration of stimulation. For this reason, GnRH antagonists might be a good treatment even for normal responder patients undergoing IVF.I documenti in SFERA sono protetti da copyright e tutti i diritti sono riservati, salvo diversa indicazione.
